Molecular imaging biomarkers for immune checkpoint inhibitor therapy
- PMID: 32042331
- PMCID: PMC6993216
- DOI: 10.7150/thno.38339
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
Abstract
Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the patients' immune system, resulting in a T cell mediated anti-tumor response. These therapies are effective in multiple different tumor types. Unfortunately, a substantial group of patients do not respond to ICIs. Molecular imaging, using single-photon emission computed tomography (SPECT) and positron emission tomography (PET), can provide non-invasive whole-body visualization of tumor and immune cell characteristics and might support patient selection or response evaluations for ICI therapies. In this review, recent studies with 18F-fluorodeoxyglucose-PET imaging, imaging of immune checkpoints and imaging of immune cells will be discussed. These studies are until now mainly exploratory, but the first results suggest that molecular imaging biomarkers could have a role in the evaluation of ICI therapy.
Keywords: biomarkers; immune checkpoint inhibitor; immunotherapy.; molecular imaging; positron emitting tomography.
© The author(s).
Conflict of interest statement
Competing Interests: E.G.E. de Vries reports institutional financial support for her advisory role from Daiichi Sankyo, Merck, NSABP, Pfizer, Sanofi, Synthon and for clinical trials or contracted research from Amgen, AstraZeneca, Bayer, Chugai Pharma, CytomX Therapeutics, G1 Therapeutics, Genentech, Nordic Nanovector, Radius Health, Roche, Synthon. S.F. Oosting reports institutional financial support for clinical trials or contracted research from Celldex, Pfizer, Novartis, Bristol Myers Squibb, Kura Oncology, MedImmune, Roche, Merck Sharp & Dohme. A.J. van der Wekken reports institutional financial support for his advisory role from Pfizer, Boehringer-Ingelheim, Roche (diagnostics), Astra Zeneca and institutional financial support for clinical trials from AstraZeneca. All remaining authors have declared no conflicts of interest.
Figures

Similar articles
-
Programmed Cell Death-1/Ligand-1 PET Imaging: A Novel Tool to Optimize Immunotherapy?PET Clin. 2020 Jan;15(1):35-43. doi: 10.1016/j.cpet.2019.08.008. Epub 2019 Oct 29. PET Clin. 2020. PMID: 31735300 Review.
-
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules. 2021 Apr 11;26(8):2201. doi: 10.3390/molecules26082201. Molecules. 2021. PMID: 33920423 Free PMC article.
-
Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.Eur J Nucl Med Mol Imaging. 2023 May;50(6):1671-1688. doi: 10.1007/s00259-022-06084-1. Epub 2023 Jan 9. Eur J Nucl Med Mol Imaging. 2023. PMID: 36622406 Free PMC article. Review.
-
PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.Front Immunol. 2022 Oct 20;13:1049043. doi: 10.3389/fimmu.2022.1049043. eCollection 2022. Front Immunol. 2022. PMID: 36341331 Free PMC article. Review.
-
Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing.Bioconjug Chem. 2020 Feb 19;31(2):404-415. doi: 10.1021/acs.bioconjchem.9b00851. Epub 2020 Jan 27. Bioconjug Chem. 2020. PMID: 31951380 Review.
Cited by
-
Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor.Int J Mol Sci. 2023 Dec 5;24(24):17132. doi: 10.3390/ijms242417132. Int J Mol Sci. 2023. PMID: 38138961 Free PMC article.
-
Radiomic biomarkers of tumor immune biology and immunotherapy response.Clin Transl Radiat Oncol. 2021 Apr 7;28:97-115. doi: 10.1016/j.ctro.2021.03.006. eCollection 2021 May. Clin Transl Radiat Oncol. 2021. PMID: 33937530 Free PMC article. Review.
-
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET.ACS Cent Sci. 2021 Oct 27;7(10):1638-1649. doi: 10.1021/acscentsci.1c00529. Epub 2021 Sep 2. ACS Cent Sci. 2021. PMID: 34729407 Free PMC article.
-
Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction.Biomark Res. 2023 Jun 2;11(1):57. doi: 10.1186/s40364-023-00498-1. Biomark Res. 2023. PMID: 37268978 Free PMC article. Review.
-
The development process of 'fit-for-purpose' imaging biomarkers to characterize the tumor microenvironment.Front Med (Lausanne). 2024 May 16;11:1347267. doi: 10.3389/fmed.2024.1347267. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38818386 Free PMC article. Review.
References
-
- Polk A, Svane IM, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer - Current status. Cancer Treat Rev. 2018;63:122–34. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous